| Latest Keryx Biopharmaceuticals News Headlines | | Date | Time | Source | | | 11/11/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annua
Updated Analyses of Phase 1/2 Clinical Trial of KRX-0401 in Combination with Bortezomib (+/- Dexamethasone) to be Presented on Saturday, December 5, 2009
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that data from its Phase 1/2 clinical trial of KRX-0401 (perifosine... More...>> |
| 11/09/2009 | 4:30PM | PRNUS | Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Keryx to Host Investor Conference Call on Tuesday, November 10, 2009 at 8:30am EST
NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment... More...>> |
| 11/04/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals to Present at the Merriman Curhan Ford 6th Annual Investor Summit
Presentation Scheduled for Tuesday, November 10th at 3:40 PM ET
NEW YORK, Nov. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Merriman Curhan Ford 6th Annual Investor Summit being held in... More...>> |
| 10/08/2009 | 8:30AM | PRNUS | Phase 2 Study of KRX-0401 (Perifosine) in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Open
NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced today the initiation of a Phase 2 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for relapsed or refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). This Phase... More...>> |
| 09/29/2009 | 8:00AM | PRNUS | Updated Single Agent Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Carcinoma Reported
KRX-0401 (Perifosine) Continues to Demonstrate Impressive Efficacy, Safety and Tolerability in Metastatic Renal Cell Carcinoma Patients who Progressed after Failing Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor
NEW YORK, Sept. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX... More...>> |
| 09/29/2009 | 8:00AM | PRNUS | Updated Single Agent Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Carcinoma Reported
KRX-0401 (Perifosine) Continues to Demonstrate Impressive Efficacy, Safety and Tolerability in Metastatic Renal Cell Carcinoma Patients who Progressed after Failing Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor
NEW YORK, Sept. 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX... More...>> |
| 09/25/2009 | 5:25PM | PRNUS | Keryx Biopharmaceuticals, Inc. to Raise $20 Million in Registered Direct Offering
NEW YORK, Sept. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (the "Company") (NASDAQ:KERX), has entered into definitive agreements to sell 8 million shares of its common stock at a price per share of $2.50 pursuant to a registered direct offering to several select institutional investors, representing... More...>> |
| 09/23/2009 | 8:30AM | PRNUS | Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the
Serum phosphorus well-controlled and drug well-tolerated in 29 patients followed for up to one year Data suggests the potential for reduced need of IV iron and EPO
NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced results of the Open Label Extension (OLE) trial... More...>> |
| 09/14/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals' Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Select
NEW YORK, Sept. 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Phase 2 data of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, as a single agent in the treatment of advanced metastatic renal cell cancer, has been selected for oral presentation... More...>> |
| 08/05/2009 | 4:45PM | PRNUS | Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Keryx to Host Investor Conference Call on Thursday, August 6, 2009 at 8:30am EDT
NEW YORK, Aug. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for... More...>> |
| 08/04/2009 | 4:30PM | PRNUS | Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8
NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) will hold a conference call on Thursday, August 6, 2009 at 8:30 a.m. EDT to discuss the second quarter 2009 financial results and business outlook for the remainder of 2009. Ron Bentsur, Chief Executive Officer of the Company, will... More...>> |
| 08/04/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
Keryx to Receive $3,500,000 and Deliver Sulonex Data and Intellectual Property to Alfa Wassermann
NEW YORK, Aug. 4 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced today that the Company and Alfa Wassermann S.p.A. have settled a dispute over issues arising from the terminated license agreement... More...>> |
| 07/14/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) announced today the initiation of a Phase 1 clinical study to evaluate KRX-0401 (perifosine) as a single agent treatment for recurrent solid tumors in pediatric patients. This Phase 1 study is now open for enrollment at Memorial... More...>> |
| 06/15/2009 | 9:49AM | PRNUS | PennyStockExplosion.com Issues Technical Trade Alerts on Cancer Stocks on the Move Today: HEB, GNBT, CTIC, KERX, DNDN
BOSTON, June 15 /PRNewswire/ -- PennyStockExplosion.com is pleased to offer its stock alerts service to the investing community. Investors who are interested in stocks on the move and in the news can receive FREE Alerts by visiting the following link: http://www.pennystockexplosion.com/
Today's focused alerts include:... More...>> |
| 06/09/2009 | 10:24AM | PRNUS | Trade Alerts on Active Stocks: Apple, Keryx, Angiotech, General Mills, Pep Boys and Talbots; Issued by InvestorSoup.com
DALLAS, June 9 /PRNewswire/ -- InvestorSoup.com announces the availability of stock alerts on six stocks ready to move in Tuesday's market. Each stock alert includes recent news, trading activity, technical analysis and relevant market research you need to know.
Investors can view all of the daily stock alerts for... More...>> |
| 06/09/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
NEW YORK, June 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that on June 5, 2009, it received a letter from the NASDAQ Listing Qualifications Hearings Panel granting the Company an extension through August 31, 2009, to regain compliance with Nasdaq Listing Rule 5550(b), which... More...>> |
| 06/08/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatem
NEW YORK, June 8 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced results of the Phase 2 study of Zerenex (ferric citrate) for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on thrice weekly hemodialysis... More...>> |
| 06/01/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study
KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer
NEW YORK, June 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) yesterday announced data... More...>> |
| 05/31/2009 | 8:30AM | PRNUS | Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of
KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer
NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced data... More...>> |
| 05/29/2009 | 4:30PM | PRNUS | Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in
KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor
NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced... More...>> |
|